Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research
NCT06049485 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-09-22
Summary
Historically, participation in medical studies is highly skewed towards particular demographic groups of people.
This research will invite several participants to gather a wide range of information on clinical trial experiences for follicular lymphoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of follicular lymphoma.
The data collected from this study will help improve future outcomes for all follicular lymphoma patients as well as those in under-represented demographic groups.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-31
- Primary Completion
- 2025-10-31
- Completion
- 2026-10-31
Countries
- United States
Study Locations
More Related Trials
-
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
NCT00097565 ·Status: COMPLETED
-
Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea
NCT04048395 ·Status: UNKNOWN
-
S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone
NCT00933127 ·Status: COMPLETED
-
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
NCT00490529 ·Status: COMPLETED ·Phase: PHASE2
-
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
NCT00651443 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase II Trial of Intermediate Radiation Dose For Lymphoma
NCT05284825 ·Status: UNKNOWN ·Phase: NA
-
Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab
NCT01150643 ·Status: COMPLETED
-
Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma
NCT01130194 ·Status: COMPLETED ·Phase: PHASE2
-
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00324831 ·Status: SUSPENDED ·Phase: PHASE3
-
Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden
NCT00136552 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Study for Patients With Follicular Lymphoma Needing Treatment
NCT00140569 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma
NCT00641095 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
NCT03789240 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
NCT05888493 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma
NCT00774826 ·Status: UNKNOWN ·Phase: PHASE3
-
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
NCT00227695 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
NCT01829568 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
NCT05816850 ·Status: RECRUITING
-
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
NCT06284122 ·Status: RECRUITING ·Phase: PHASE3
-
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma
NCT05338879 ·Status: COMPLETED
-
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
NCT01057459 ·Status: COMPLETED
-
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
NCT01650701 ·Status: COMPLETED ·Phase: PHASE3
-
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
NCT02871219 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
NCT00003204 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
NCT01476787 ·Status: COMPLETED ·Phase: PHASE3